Registration is open for the 16th Annual Drug Discovery Summit in Berlin, 8th & 9th June 2015
25 February 2015 | By Oxford Global
Oxford Global are proud to present its 16th Annual Drug Discovery Congress will be on the 8th and 9th of June 2015...
List view / Grid view
News
Mundipharma launches Remsima®▼ (infliximab), a new-generation value-based monoclonal antibody, in six European markets
25 February 2015 | By Mundipharma
Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets...
Prexton Therapeutics raises €8.7 million ($10 million) in a Series A round
24 February 2015 | By Prexton Therapeutics
Swiss based startup attracts venture funding from leading European VC firms to address Parkinson’s disease and other CNS conditions...
Data show the world’s first EMA-approved biosimilar monoclonal antibody Remsima™ could reduce cost of treating Crohn’s disease by up to €336 million over five years
23 February 2015 | By Celltrion Healthcare
Cost savings could help improve patient access to life-changing treatment...
Eyevensys announced appointment of Dr Violaine Desort-Henin as Clinical Director
23 February 2015 | By Eyevensys
Eyevensys, an innovative ophthalmic therapy company, announced the appointment Dr. Violaine Desort-Hénin as Clinical Director...
Cancer risk linked to DNA ‘wormholes’
19 February 2015 | By The Institute of Cancer Research
Single-letter genetic variations within parts of the genome once dismissed as ‘junk DNA’ can increase cancer risk through wormhole-like effects on far-off genes, new research shows...
Patrice Denèfle is the new Head of the Roche Institute for Research and Translational Medicine, created by Roche France
19 February 2015 | By Roche
The Institute’s mission is to consolidate and expand R&D partnerships in France with Centres of Excellence in translational Medicine...
Leading dementia charity launches three Drug Discovery Institutes
18 February 2015 | By Alzheimer’s Research UK
Institutes at Universities of Cambridge, Oxford and UCL will form £30m Drug Discovery Alliance...
Two major scientific articles validate Effimune’s drug candidate
13 February 2015 | By Effimune
Two major scientific articles validate Effimune’s drug candidate and reinforce the proof of concept of the technology aimed at regulating the immune system...
Key bioelectronic medical patent for cancer treatment issued by the U.S. Patent & Trademark Office
11 February 2015 | By Cancer-Code Corporation
Another foundation patent in the burgeoning field of bioelectronic medicine, specifically for treating cancer patients...
SensiQ Technologies and Inventiva set up a European Center of Excellence in surface plasmon resonance (SPR) technologies
9 February 2015 | By SensiQ Technologies/Inventiva
Based in Dijon, France, the Center will boast a unique offering for drug discovery in Europe, combining Inventiva’s screening platforms and libraries with SensiQ’s instrumentation...
Nobel Laureate’s stem cell company Cell Therapy Limited sets new crowdfunding record raising £691,000 on Crowdcube
9 February 2015 | By Cell Therapy Ltd
UK biotech company Cell Therapy Limited has raised over £691,000 on Crowdcube to fund its breakthrough stem cell medicine, Heartcel™, which regenerates heart muscle to treat heart failure...
Genticel presents pipeline development at EUROGIN congress held in Seville, Spain
6 February 2015 | By Genticel
Genticel announces that data obtained with ProCervix, its lead therapeutic vaccine, will be presented in the EUROGIN (EUropean Research Organisation on Genital Infection and Neoplasia) 2015 Congress taking place at the FIBES II Conference and Exhibition Centre in Seville, Spain on February 4 – 7...
Two major studies strengthen case for prostate cancer drug before chemotherapy
5 February 2015 | By The Institute of Cancer Research
Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown...
TxCell reports revenues for 2014 and updates on upcoming milestones
5 February 2015 | By TxCell
TxCell, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, reports its revenues as of December 31, 2014 and updates on forthcoming milestones...
